LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

4.21

Buy Sell

Overview

Share price change

24h

Current

Min

4.09

Max

4.24

Key metrics
By Trading Economics
Income	-2.4M -33M
Sales	-1.3M 5.2M
Profit margin	-641.962
Employees	172
EBITDA	-1.9M -36M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+320.62% upside

Dividends
By Dow Jones
Next Earnings	12 lis 2025

Market Stats
By TradingEconomics
Market Cap	77M 255M
Previous open	4.21
Previous close	4.21

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 lis 2025, 21:06 UTC

Major Market Movers

JBS Down After Trump Calls for Probe into Meat-Packing Companies

7 lis 2025, 22:36 UTC

Earnings

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 lis 2025, 22:22 UTC

Earnings

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 lis 2025, 22:03 UTC

Earnings

Constellation Software 3Q Rev $2.95B >CSU.T

7 lis 2025, 22:03 UTC

Earnings

Constellation Software 3Q Net $210M >CSU.T

7 lis 2025, 22:03 UTC

Earnings

Constellation Software 3Q EPS $9.89 >CSU.T

7 lis 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

7 lis 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

7 lis 2025, 20:59 UTC

Earnings

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7 lis 2025, 20:26 UTC

Market Talk

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7 lis 2025, 20:22 UTC

Earnings

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7 lis 2025, 20:04 UTC

Market Talk

Oil Futures Close Choppy Week With Losses -- Market Talk

7 lis 2025, 19:34 UTC

Market Talk

Gold Posts Small Gain for Week -- Market Talk

7 lis 2025, 19:31 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7 lis 2025, 19:17 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7 lis 2025, 19:09 UTC

Earnings

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7 lis 2025, 19:08 UTC

Earnings

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7 lis 2025, 18:31 UTC

Market Talk

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7 lis 2025, 17:27 UTC

Market Talk

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7 lis 2025, 17:20 UTC

Market Talk

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7 lis 2025, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7 lis 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7 lis 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

7 lis 2025, 17:17 UTC

Acquisitions, Mergers, Takeovers

Satair Expects to Complete Purchase in Early 2026

7 lis 2025, 17:17 UTC

Acquisitions, Mergers, Takeovers

Satair: Deal Includes Unical's and ecube's Seven Operational Sites and Offices, With Combined 2024 Rev of $298M and Headcount of 413

7 lis 2025, 17:15 UTC

Acquisitions, Mergers, Takeovers

Airbus Unit Satair to Buy Unical Aviation From Platinum Equity

7 lis 2025, 17:09 UTC

Market Talk

PENN Is Falling Further Behind Competitors -- Market Talk

7 lis 2025, 16:49 UTC

Market Talk

Losing ESPN Partnership Will Hurt PENN -- Market Talk

7 lis 2025, 16:24 UTC

Market Talk

OPEC+'s Output Hike Pause Comes Amid Excess Supply, Lower Spare Capacity -- Market Talk

7 lis 2025, 16:17 UTC

Market Talk

Oil Market Faces Oversupply But "Glut" Might Be Overblown -- Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

320.62% upside

12 Months Forecast

Average 17.75 USD 320.62%

High 30 USD

Low 11 USD

Based on 5 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.